Dr. Reddy’s Labs to Rename Semaglutide Drug to 'Olymra' Amid Court Concerns
Synopsis
In a pivotal move, Dr. Reddy’s Laboratories will rebrand its semaglutide drug from 'Olymviq' to 'Olymra' following court concerns about potential confusion with Novo Nordisk's 'Ozempic'. This decision highlights the growing competition in India's generic drug market post-patent expiry.
Key Takeaways
Reddy’s is changing the name of its semaglutide drug to avoid confusion.
The new brand name will be 'Olymra'.
This decision follows concerns raised by the Delhi High Court.
The company aims to enhance patient safety and clarity in branding.
India is witnessing increased competition in the generic pharmaceuticals market.
New Delhi, March 27 (NationPress) In a significant development, Dr. Reddy’s Laboratories, a leading pharmaceutical company, informed the Delhi High Court on Friday about its decision to rebrand its semaglutide medication from 'Olymviq' to 'Olymra', according to reports. The court's concerns highlighted that the current brand name might create confusion within the pharmaceutical community.
This legal matter arises as India begins to embrace generic versions of semaglutide following the expiration of patents, intensifying competition among pharmaceutical companies and leading to branding disputes.
Dr. Reddy’s also mentioned it is the first Indian company to gain approval from the Drugs Controller General of India for generic semaglutide.
The controversy revolves around the potential similarity between 'Olymviq' and 'Ozempic', a well-known diabetes and weight management medication, as noted by NDTV Profit.
Previously, the company announced the launch of its injectable semaglutide, branded as 'Obeda', which represents a crucial step towards increasing the availability of GLP-1 receptor agonist treatments for managing Type 2 diabetes in India.
“This launch aims to enhance access to advanced diabetes therapies and meet the pressing needs of patients in India,” stated Erez Israeli, CEO of Dr. Reddy’s Laboratories.
During the court proceedings, the judge raised concerns about the phonetic and visual likeness of the two drug names, indicating that such similarities could cause confusion for patients, healthcare professionals, and pharmacists, as reported.
Prior to this, the court had instructed Dr. Reddy’s to pause the marketing and distribution of the product due to apprehensions regarding its resemblance to Novo Nordisk’s “Ozempic.”
Novo Nordisk markets semaglutide under various names, including Ozempic, Wegovy, and Rybelsus.
As of 2 p.m., shares of Dr. Reddy’s Laboratories saw a decline of approximately 2% at Rs 1,274.75, marking an intraday low on the BSE.
Point of View
I view Dr. Reddy's decision to rename its semaglutide drug as a proactive response to legal scrutiny. The rebranding initiative reflects the importance of distinguishing pharmaceutical products in a highly competitive market, especially as India embraces generic alternatives. This move may also enhance patient safety by reducing the risk of confusion among healthcare providers.
NationPress
3 Jul 2026
Frequently Asked Questions
Why is Dr. Reddy’s Labs changing the drug name?
Dr. Reddy’s Labs is changing the drug name from 'Olymviq' to 'Olymra' to avoid confusion with Novo Nordisk's 'Ozempic', following concerns raised in the Delhi High Court.
What is semaglutide used for?
Semaglutide is primarily used for the management of Type 2 diabetes and weight loss.
What is the significance of this rebranding?
The rebranding signifies Dr. Reddy's commitment to patient safety and legal compliance as India opens its market to generic drugs.
How has the market responded to this news?
Following the announcement, shares of Dr. Reddy's Laboratories experienced a slight decline, trading around 2% lower.
What other brands does Novo Nordisk market semaglutide under?
Novo Nordisk markets semaglutide under several names, including Ozempic, Wegovy, and Rybelsus.
